Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.62 |
| ▸ | BTK | Q06187 | 11/20 | 0.58 |
| ▸ | ITK | Q08881 | 11/20 | 0.58 |
| ▸ | KIT | P10721 | 1/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | NEK2 | P51955 | 1/20 | 0.53 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.53 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7114155 | 0.86 | GSK3A (0.62) | BTKITKKITAAK1IGF1R | |
| SCHEMBL7117296 | 0.86 | AAK1 (0.65) | BTKITKKITRIPK1AAK1 | |
| SCHEMBL7116485 | 0.86 | AAK1 (0.60) | TNIKRIPK1AAK1IGF1R | |
| SCHEMBL7117585 | 0.85 | AXL (0.61) | NTRK1BTKITKCHEK1FGFR1 | |
| SCHEMBL4308629 | 0.85 | KIT (0.57) | NTRK1BTKITKKITAAK1 | |
| SCHEMBL7051030 | 0.85 | ADORA1 (0.53) | BTKITKAAK1IGF1R | |
| SCHEMBL7116630 | 0.84 | AAK1 (0.56) | NTRK1BTKITKCHEK1FGFR1 | |
| SCHEMBL4297488 | 0.82 | GSK3B (0.62) | NTRK1KITNEK2TNIKAAK1 | |
| SCHEMBL7118788 | 0.82 | AAK1 (0.58) | NTRK1BTKITKCHEK1FGFR1 | |
| SCHEMBL7118372 | 0.82 | CAMKK2 (0.50) | BTKITKAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| CN-101448827-A | Indole derivatives | ASTRAZENECA AB (SE) | 2009-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306126-A1 | Indole Derivatives | MTOR, IDO1, AKT1S1 | NTRK1 942/4885BTK 203/4885ITK 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.